| Literature DB >> 30652474 |
Matthew R Bockman1, Curtis A Engelhart2, Julia D Cramer3, Michael D Howe1, Neeraj K Mishra1, Matthew Zimmerman4, Peter Larson1, Nadine Alvarez-Cabrera4, Sae Woong Park2, Helena I M Boshoff5, James M Bean6, Victor G Young7, David M Ferguson1, Veronique Dartois4, Joseph T Jarrett3, Dirk Schnappinger2, Courtney C Aldrich1.
Abstract
The synthesis, absolute stereochemical configuration, complete biological characterization, mechanism of action and resistance, and pharmacokinetic properties of ( S)-(-)-acidomycin are described. Acidomycin possesses promising antitubercular activity against a series of contemporary drug susceptible and drug-resistant M. tuberculosis strains (minimum inhibitory concentrations (MICs) = 0.096-6.2 μM) but is inactive against nontuberculosis mycobacteria and Gram-positive and Gram-negative pathogens (MICs > 1000 μM). Complementation studies with biotin biosynthetic pathway intermediates and subsequent biochemical studies confirmed acidomycin inhibits biotin synthesis with a Ki of approximately 1 μM through the competitive inhibition of biotin synthase (BioB) and also stimulates unproductive cleavage of S-adenosyl-l-methionine (SAM) to generate the toxic metabolite 5'-deoxyadenosine. Cell studies demonstrate acidomycin selectively accumulates in M. tuberculosis providing a mechanistic basis for the observed antibacterial activity. The development of spontaneous resistance by M. tuberculosis to acidomycin was difficult, and only low-level resistance to acidomycin was observed by overexpression of BioB. Collectively, the results provide a foundation to advance acidomycin and highlight BioB as a promising target.Entities:
Keywords: Mycobacterium tuberculosis; accumulation; acidomycin; antimetabolite; biotin biosynthesis; biotin synthase; tuberculosis
Mesh:
Substances:
Year: 2019 PMID: 30652474 PMCID: PMC6724193 DOI: 10.1021/acsinfecdis.8b00345
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084